Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Áø´Ü ¹æ¹ýº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Exocrine Pancreatic Insufficiency Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Method (Laboratory, Imaging), By End-use (Hospitals & Clinics, Research Institutes), By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1511791
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 125 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,194,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,571,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,325,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 54¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2030³âÀÇ CAGRÀº 7.2%·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

¿ÜºÐºñ ÃéÀå ±â´É ºÎÀü(EPI) Áø´ÜÀº ƯÈ÷ ´Ù¾çÇÑ È¯ÀÚ Áý´Ü¿¡¼­ ³ôÀº À¯º´·ü°ú ¸î °¡Áö ±Ùº»ÀûÀÎ ¿øÀΰúÀÇ ¿¬°ü¼ºÀ» °í·ÁÇÒ ¶§ ÀÌ ÁúȯÀÇ ½Äº°°ú °ü¸®¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Áø´ÜÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¸¸¼º ÃéÀå¿° ȯÀÚÀÇ À¯º´·üÀÔ´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é ¸¸¼º ÃéÀå¿° Áø´ÜÀ» ¹ÞÀº ȯÀÚÀÇ ¾à 60-90%¿¡¼­ Áø´Ü ÈÄ 10-12³â À̳»¿¡ EPI°¡ ¹ßº´ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¸¸¼º ÃéÀå¿°Àº EPIÀÇ Áß¿äÇÑ ¿øÀÎÀÌ¸ç »ó´ëÀûÀ¸·Î ³ôÀº À¯º´·üÀº Á¶±â ¹ß°ß ¹× °ü¸®ÀÇ Á߿伺À» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÁøÇ༺ ÃéÀå¾Ïµµ ÀÌ Áúȯ°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ´Â Áúȯ Áß ÇϳªÀÔ´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é ÁøÇ༺ ÃéÀå¾Ï ȯÀÚÀÇ 66-92%°¡ EPI¸¦ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ¿¡¼­ EPI¸¦ Á¶±â¿¡ Áø´ÜÇÏ´Â °ÍÀº Áõ»ó °ü¸®¸¦ °³¼±ÇÏ°í »îÀÇ ÁúÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¿°Áõ¼ºÀåÁúȯ(IBD)µµ EPI¿Í °ü·ÃÀÌ ÀÖÀ¸¸ç, ¿¬±¸¿¡ µû¸£¸é IBD ȯÀÚÀÇ 14%¿¡¼­ 74%°¡ EPI¸¦ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ¿¡¼­ ÃéÀå¿ÜºÐºñ±â´ÉºÎÀüÀ» Àû½Ã¿¡ Áø´ÜÇϰí Ä¡·áÇϸé Áõ»óÀ» ¿ÏÈ­ÇÏ°í ¿µ¾ç »óŸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ ºñ¸¸ ¼ö¼úÀ» ¹ÞÀº ȯÀÚµéÀº È¿¼Ò ¹× ¿µ¾ç º¸ÃæÁ¦¸¦ º¹¿ëÇϰí ÀÖÀ½¿¡µµ ºÒ±¸Çϰí EPI°¡ ¹ß»ýÇÒ À§ÇèÀÌ ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ È¯ÀÚ±º¿¡¼­ Ãé¿ÜºÐºñ±â´É Àå¾Ö¸¦ È®ÀÎÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Áø´Ü °Ë»çÀÇ Á߿伺À» °­Á¶ÇÕ´Ï´Ù. ¶ÇÇÑ HIV/AIDS ȯÀÚÀÇ EPI À¯º´·üÀº 26%-45%·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ¿¡¼­ ÃéÀå¿ÜºÐºñ±â´ÉºÎÀüÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â °ÍÀº ¿µ¾ç »óÅÂ¿Í Àü¹ÝÀûÀÎ °Ç°­ °á°ú¸¦ ÃÖÀûÈ­ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

ÃéÀå¿ÜºÐºñºÎÀüÁõ°ú °ü·ÃµÈ º´Å»ý¸®°¡ ´Ù¾çÇϱ⠶§¹®¿¡ Á¾ÇÕÀûÀÎ Áø´ÜÀû Á¢±ÙÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ È¯ÀÚ±º¿¡¼­ ³ôÀº À¯º´·ü, ¸¸¼º ÃéÀå¿° ¹× ÃéÀå¾Ï°ú °°Àº ¸¸¼ºÁúȯ°úÀÇ ¿¬°ü¼º, È¿°úÀûÀÎ °ü¸®¿Í ȯÀÚ ¿¹ÈÄ °³¼±À» À§ÇÑ Á¶±â ¹ß°ßÀÇ Á߿伺 µîÀÌ Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó Á¶±â ¹ß°ß°ú °³º°È­µÈ °ü¸®°¡ Á¡Á¡ ´õ °¡´ÉÇØÁ® ȯÀÚ Ä¡·á¿Í ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ChiRhoClin, Inc., Certest Biotec, ScheBo Biotech AG, Immundiagnostik AG, Laboratory Corporation of America Holdings¿Í °°Àº ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷Àº Ãé¿ÜºÐºñ±â´É Àå¾Ö Áø´Ü ±â¼ú Çõ½ÅÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº Áö¼ÓÀûÀ¸·Î Á¦Ç° È®Àå¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 6¿ù, CERTEST BIOTECÀº 8¿ù 4ÀϺÎÅÍ 8ÀϱîÁö ͏®Æ÷´Ï¾Æ¿¡¼­ ¿­¸®´Â Á¦71ȸ AACC ¿¬·Ê Çмú´ëȸ ¹× ÀÓ»ó½ÇÇè½Ç Àü½Ãȸ¿¡ Âü°¡ÇÏ¿© Ãֽа³¹ß Á¦Ç°À» Àü½ÃÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù.

ÃéÀå¿ÜºÐºñ±â´ÉºÎÀü Áø´Ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü ½ÃÀå : Áø´Ü ¹æ¹ý ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå Ãé¿ÜºÐºñ±â´É ºÎÀü Áø´Ü ½ÃÀå : Áø´Ü ¹æ¹ý°ú ÃÖÁ¾ ¿ëµµº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Exocrine Pancreatic Insufficiency Diagnostics Market Growth & Trends:

The global exocrine pancreatic insufficiency diagnostics market size is anticipated to reach USD 5.44 billion by 2030 and is growing at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Exocrine pancreatic insufficiency (EPI) diagnostics are crucial for identifying and managing the condition, especially considering its high prevalence in various patient populations and its association with several underlying causes. One of the major driving factors for diagnostics is the prevalence of patients with chronic pancreatitis. Studies have shown that EPI is prevalent in about 60% to 90% of patients diagnosed with chronic pancreatitis within 10 to 12 years of diagnosis. Chronic pancreatitis is a significant contributor to EPI, and its relatively high prevalence underscores the importance of early detection and management.

Furthermore, advanced pancreatic cancer is another condition strongly associated with the disease. Research indicates that between 66% to 92% of patients with advanced pancreatic cancer develop EPI. Early diagnosis of EPI in these patients can lead to better management of symptoms and improved quality of life. Inflammatory bowel disease (IBD) is also linked to EPI, with studies suggesting that between 14% and 74% of IBD patients may suffer from EPI. Timely diagnosis and treatment of exocrine pancreatic insufficiency in these patients can help alleviate symptoms and improve nutritional status.

In addition, patients undergoing bariatric surgery are at risk of developing EPI despite receiving enzymatic and nutritional supplements. This highlights the importance of ongoing monitoring and diagnostic testing to identify exocrine pancreatic insufficiency in this patient population. Moreover, the prevalence of EPI in patients with HIV/AIDS is estimated to be between 26% and 45%. Early detection of exocrine pancreatic insufficiency in these individuals is essential for optimizing nutritional status and overall health outcomes.

The diverse range of conditions associated with EPI underscores the need for comprehensive diagnostic approaches. Factors driving the demand for exocrine pancreatic insufficiency diagnostics include high prevalence in various patient populations, the association with chronic conditions such as chronic pancreatitis and pancreatic cancer, and the importance of early detection for effective management and improved patient outcomes. As diagnostic technologies advance, early detection and personalized management will become increasingly feasible, leading to better patient care and outcomes.

Key market players such as ChiRhoClin, Inc., Certest Biotec, ScheBo Biotech AG, Immundiagnostik AG, and Laboratory Corporation of America Holdings are at the forefront of innovation in exocrine pancreatic insufficiency diagnostics. These companies are constantly focusing on expanding their products. For instance, in June 2021, CERTEST BIOTEC announced to participate and showcase its product with latest developments at 71st Annual Scientific Meeting and Exhibition of Clinical Laboratories of the AACC held from August 4 to 8 in California.

Exocrine Pancreatic Insufficiency Diagnostics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope

Chapter 4. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis

Chapter 5. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis

Chapter 6. Exocrine Pancreatic Insufficiency Diagnostics Market: Regional Estimates & Trend Analysis by Diagnostic Method, and End-use

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â